Inecalcitol

Drug Profile

Inecalcitol

Alternative Names: TX-522

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Ghent University; Katholieke Universiteit Leuven
  • Developer Hybrigenics
  • Class Alkynes; Antipsoriatics; Secosteroids; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Prostate cancer
  • Preclinical Haematological malignancies
  • Suspended Psoriasis

Most Recent Events

  • 08 Dec 2016 Updated pharmacodynamics data from a preclinical trial in Multiple myeloma and Acute myeloid leukaemia presented at the 58th Annual Meeting of the American Society of Hematology (ASH-2016)
  • 10 Nov 2016 New pharmacodynamics data from preclinical studies in Acute myeloid leukaemia and myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 01 Jun 2016 Phase-II clinical trials in Acute myeloid leukaemia (First-line therapy, Combination therapy) in France, USA, France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top